Important regulatory notice. No peptide sold as a research-use-only reference compound is licensed by the MHRA as a wound-healing medicine in the United Kingdom. This page is a literature-context overview of compound families discussed in published wound-healing research. It is not personal-use guidance. Peptides Lab UK supplies research-use-only laboratory reference compounds. Products are not for human or veterinary use. Wound care in any clinical context is a matter for a registered prescriber.
Quick research summary. The published wound-healing literature spans cell-culture, ex-vivo tissue and small-animal model studies of haemostasis, the inflammatory phase, granulation tissue formation, and re-epithelialisation. Several peptide families appear in this research record. None is a licensed UK wound-healing treatment in the research-use-only category.
Wound-healing biology context
Wound healing in the published literature is described in four classic phases: haemostasis, inflammation, proliferation (granulation tissue and re-epithelialisation), and remodelling. Each phase involves a distinct set of cellular populations (platelets, neutrophils, macrophages, fibroblasts, keratinocytes), signalling pathways (growth factors including TGF-beta, VEGF and PDGF), and biochemistry (collagen synthesis, extracellular matrix turnover, angiogenesis).
Compound families that appear in the published wound-healing research record
Cell-culture and rodent-model studies have discussed several peptide families in wound-healing contexts. BPC-157 and TB-500 appear in soft-tissue repair models. Copper peptides such as GHK-Cu appear in dermal wound-healing and collagen-biochemistry research. Growth-factor mimetic peptides relevant to TGF-beta and VEGF biology appear in angiogenesis and granulation-tissue studies. Antimicrobial peptide research relevant to wound infection biology is a separate large category.
Where licensed UK wound-care medicines fit
Licensed UK wound-care interventions include surgical and dressing-based standards, infection management with regulated antimicrobials, and a small set of MHRA-licensed protein and peptide-related products in defined clinical indications. None of these are research-use-only peptide reference compounds.
UK regulatory position
No research-use-only peptide on this site is a licensed treatment for wound healing in the UK. The MHRA opened investigations in April 2026 into UK clinics making therapeutic claims about unregulated peptide products. Marketing peptides as wound-healing interventions falls inside the medicines framework.
For laboratory researchers
Wound-healing researchers may use peptide reference compounds for in-vitro and small-animal model studies. Quality requirements are batch-specific certificate of analysis, third-party HPLC purity data, mass-spectrometry identity confirmation, and clear research-use-only labelling. Peptides Lab UK supplies on that basis.
Research use only. Peptides Lab UK supplies research-use-only laboratory reference compounds with batch-specific certificates of analysis. Products are not for human or veterinary use. TB-500 also appears on the WADA Prohibited List in sport.
